{"filings":[{"id":982396,"accession_number":"0001213900-26-067555","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2026-06-11T11:55:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q3 net loss $4.2M; Phase 3 NPC trial done, NDA submission H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Rafael Holdings was $4.2M ($0.08/shr) vs $4.8M ($0.19/shr) a year ago.","Cash and equivalents stood at $30.5M as of April 30, 2026.","R&D expenses rose to $4.9M from $3.0M, driven by the March 2025 Cyclo acquisition.","Phase 3 TransportNPC trial completed last patient last visit; NDA submission expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":955036,"accession_number":"0001213900-26-067083","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2026-06-10T11:49:05+00:00","items":["7.01","2.02","8.01","9.01"],"status":"ready","headline":"Rafael Holdings announces Phase 3 TransportNPC study completion; NDA submission targeted H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed final 96-week visit in pivotal Phase 3 TransportNPC study for Trappsol Cyclo in Niemann-Pick Disease Type C.","Topline data from main cohort expected to be announced in second half of calendar 2026.","Pre-NDA meeting with FDA completed; NDA submission expected in second half of 2026.","FDA acknowledged US Expanded Access Program (EAP) can proceed.","Pediatric sub-study (0-3 years) data: 80% of patients improved or stable with no serious related adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94929,"accession_number":"0001213900-26-046380","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","2.02","8.01","9.01"],"status":"ready","headline":"Rafael Holdings subsidiary Cyclo Therapeutics licenses MIT patent for cyclodextrins in ApoE4+ Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license covers U.S. Patent No. 12285440 for cyclodextrins in ApoE4-positive Alzheimer's patients.","ApoE4 variant present in 50-70% of Alzheimer's patients; Trappsol Cyclo targets cholesterol transport in CNS.","Phase 3 results for Transport NPC program due in calendar Q3 2026, per COO Joshua Fine.","CEO Howard Jonas calls the license a transformative milestone for the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107657,"accession_number":"0001213900-26-028311","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q2 net loss $6.4M; Phase 3 trial on track for Q3 2026 top-line","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.4M ($0.13 per share) vs $4.6M ($0.19) YoY; increase due to Cyclo consolidation.","Cash and cash equivalents $37.8M as of Jan 31, 2026.","R&D expenses $4.5M (up from $0.9M YoY) driven by Cyclo acquisition and Phase 3 trial costs.","Phase 3 TransportNPC study of Trappsol Cyclo continued after DMC review; top-line results expected Q3 calendar 2026.","G&A expenses $2.3M, down from $2.6M YoY, offset by Cyclo costs and lower payroll."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":451000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107656,"accession_number":"0001213900-26-003411","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rafael Holdings shareholders approve all proposals including equity plan increase of 1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 84-87% votes for (highest: Grayson, Sieger at 86.70%).","Ratification of CohnReznick LLP as auditor passed with 99.13% votes for (6,064,445 for).","Amendment to 2021 Equity Incentive Plan approved (82.34% for), increasing share authorization by 1,000,000.","Broker non-votes of ~792,079 were present for director and equity plan votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124025,"accession_number":"0001213900-25-120691","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q1 FY2026 net loss $9.8M; Phase 3 NPC trial continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Rafael Holdings of $9.8M ($0.19/shr), widened from $9.0M ($0.37/shr) YoY.","R&D expenses $7.5M vs $1.3M YoY, driven by Cyclo Therapeutics consolidation after March 2025 acquisition.","Cash and cash equivalents $45.5M as of October 31, 2025.","CEO Howard Jonas highlighted Phase 3 TransportNPC study for Trappsol Cyclo; DMC recommended continue after 48-week data.","General & administrative expenses $2.8M vs $2.5M YoY, also due to Cyclo consolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":240000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124024,"accession_number":"0001213900-25-116951","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rafael Holdings issues warrants after Cyclo Therapeutics merger; expire Dec 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,078,796 warrants exercisable for 380,253 Class B shares at $14.19 per share.","Warrants listed on NYSE American as RFL-WT; expire at 5:00 pm EST on Dec 11, 2025.","Warrants issued in exchange for Cyclo warrants; each warrant exercisable for ~0.3525 share.","Cyclo warrants originated from Cyclo's Dec 11, 2020 public offering, adjusted per merger ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124023,"accession_number":"0001213900-25-103509","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q4 net loss $12.1M ($0.28/shr); cash $52.8M; Cyclo Phase 3 continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Rafael Holdings of $12.1M for Q4 vs $4.5M year ago; FY net loss $30.5M ($1.04/shr).","Research and development expenses rose to $7.5M in Q4 from $1.5M year ago on Cyclo Therapeutics consolidation.","Closed $25M rights offering in June 2025, including $21M backstop from the Jonas family; cash $52.8M at July 31.","Cyclo’s Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1 continues after DMC review at 48 weeks.","Joshua Fine elected Chief Operating Officer effective August 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124022,"accession_number":"0001213900-25-103087","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rafael Holdings appoints former Congressman Alan Grayson to Board, fills vacancy from Greenberg's passing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Grayson, former U.S. Congressman (2009-2011, 2013-2017), appointed to Board effective Oct 23, 2025.","Grayson will serve on Compensation, Corporate Governance and Nominating Committees.","Markus Sieger, existing director, appointed Chair of Audit Committee and Lead Independent Director.","Changes follow the passing of Lead Independent Director Stephen Greenberg, who served since March 2018."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124021,"accession_number":"0001213900-25-097965","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rafael Holdings posts investor presentation; no new material details","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted October 10, 2025, on company IR website.","Filing includes only title slide and forward-looking statements; no financial data or guidance.","No operational updates, revenue figures, or strategic changes disclosed.","Exhibit 99.1 contains no substantive business information beyond boilerplate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140694,"accession_number":"0001213900-25-073104","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rafael Holdings CMO resigns, appoints Joshua Fine COO; severance agreements disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Goldberg resigned as CMO effective July 31, 2025; receives $218,195 severance plus 99,429 shares vesting Nov 4, 2025.","Joshua Fine appointed COO; base salary increased to $428,000, options with $25,000 Black-Scholes value.","N. Scott Fine receives $852,168 severance over 36 installments; continues vesting on unvested equity as Vice Chairman.","Rafael Holdings substituted for Cyclo Therapeutics as employer under Fine's amended employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140693,"accession_number":"0001213900-25-065353","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Rafael Holdings elects N. Scott Fine as ex-officio director; Cyclo CEO departs with $852K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["N. Scott Fine elected as ex-officio (non-voting) director of Rafael Holdings.","Fine resigned as CEO of Cyclo Therapeutics (subsidiary), effective July 31, 2025.","Severance payment of $852,168 in 36 semi-monthly installments plus continued equity vesting.","Board amended bylaws to authorize ex-officio directors and vice chairman officer position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158428,"accession_number":"0001213900-25-055402","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rafael Holdings: Phase 3 Trappsol Cyclo NPC1 study continues after DMC interim review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DMC recommends continuation of 96-week TransportNPC study after 48-week interim safety/efficacy analysis.","Trappsol Cyclo well-tolerated; safety profile consistent with prior Phase 1/2 and open-label studies.","FDA accepted statistical analysis plan for the TransportNPC study.","Rafael closed $25M rights offering earlier June to support strategic objectives, including NPC program.","Study is described as most comprehensive controlled pivotal study for NPC in patient size and global footprint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158427,"accession_number":"0001213900-25-053266","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q3 net loss narrows to $4.8M; Phase 3 data expected this month","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Rafael Holdings of $4.8M ($0.19 per share) vs. $32.4M loss ($1.36) in Q3 last year.","Cash and equivalents of $37.9M at April 30, 2025; $25M rights offering closed June 4 with net proceeds of $24.9M.","Cyclo Therapeutics merger completed March 25, 2025; TransportNPC Phase 3 trial fully enrolled for NPC1.","48-week interim analysis results for Trappsol Cyclo expected later this month.","R&D expenses rose to $3.0M and G&A to $3.2M due to Cyclo consolidation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":567000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158426,"accession_number":"0001213900-25-051166","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Rafael Holdings completes rights offering raising ~$24.9M net; backstop purchase by CEO for $21M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering: 3,130,480 shares subscribed at $1.28 for gross proceeds of $4.0M from non-backstop holders.","Backstop purchase: Howard Jonas and related parties to buy 16,400,770 shares at $1.28, aggregate $20.99M.","Net proceeds of ~$24.9M to fund regulatory approval efforts and potential launch of Trappsol Cyclo for NPC1.","Post-closing shares outstanding: ~50.9M Class B common and 787k Class A common (convertible 1:1).","Backstop shares issued in reliance on Section 4(a)(2) exemption; purchasers are accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158422,"accession_number":"0001213900-25-045986","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K/A","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rafael Holdings updates subscription rights for public warrants in $25M rights offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of Public Warrants receive 0.3525 subscription right per warrant; three warrants yield one full right.","Each full subscription right allows purchase of 0.603 Class B share at $1.28 per share.","Executive Chairman Howard Jonas will backstop any unsubscribed shares under Standby Purchase Agreement.","Subscription period expires 5:00 PM ET on May 29, 2025; rights are non-transferable.","Rights offering supports development and potential launch of Trappsol Cyclo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158425,"accession_number":"0001213900-25-040209","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Rafael Holdings launches $25M rights offering backstopped by Chairman Howard Jonas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights offering to raise $25M at $1.28/share; record date May 9, 2025.","Howard Jonas (executive chairman) will purchase any unsubscribed shares at same price.","No standby fee; Jonas receives only reimbursement of reasonable expenses.","Backstop private placement to close within 10 days after rights offering ends.","Rights offering may be terminated by Company before closing or by June 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158421,"accession_number":"0001213900-25-039440","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K/A","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rafael Holdings revises rights offering ratio to 0.603 shares per right at $1.28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each subscription right now buys 0.603 Class B shares at $1.28, up from previously announced 0.526.","Rights offering expected to raise approximately $25 million for development of Trappsol Cyclo.","Record date May 9, 2025; subscription period runs May 13-29, 2025, 5 PM ET.","Howard Jonas to execute Standby Purchase Agreement for any unsubscribed shares at same price.","SEC registration statement effective April 29, 2025; offering made via prospectus supplement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158424,"accession_number":"0001213900-25-036845","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rafael Holdings announces $25M rights offering at $1.28/share, backstopped by Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of up to $25M via non-transferable rights: each right buys 0.526 share at $1.28.","Record date May 9, 2025; subscription period May 13-29, 2025.","Howard Jonas, Executive Chairman, fully backstops any unsubscribed shares.","Proceeds to fund potential launch of Trappsol Cyclo if positive interim Phase 3 data.","SEC registration declared effective April 29, 2025; rights are non-transferable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158420,"accession_number":"0001213900-25-036180","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K/A","filed_at":"2025-04-28T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Rafael acquires Cyclo; Cyclo's 2024 net loss $23.3M, accumulated deficit $107.2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cyclo's 2024 net loss $23.3M ($0.81/share), revenue $0.9M, accumulated deficit $107.2M.","Cash and equivalents $0.5M at Dec 31, 2024; negative working capital $16.8M.","Rafael loaned $21M to Cyclo via convertible notes; all debt forgiven upon merger close.","Exchange ratio finalized at 0.3535 Rafael shares per Cyclo share, valuing Cyclo at $0.95.","Merger closed March 25, 2025; Cyclo now operates as Cyclo Therapeutics, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158423,"accession_number":"0001213900-25-035089","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rafael Holdings CEO Bill Conkling to step down; Executive Chairman Howard Jonas to become CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Conkling resigns as CEO and President effective May 31, 2025; Howard Jonas appointed CEO and President effective June 1, 2025.","Conkling to receive consulting agreement with $100,000 annual fee and accelerated vesting of options and restricted stock; no cash severance.","Company focuses on Trappsol Cyclo for Niemann-Pick Disease Type C1; Phase 3 TransportNPC trial 48-week interim analysis expected mid-2025.","Conkling led merger with Cyclo Therapeutics prior to departure; Jonas previously served as CEO from 2018 to 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176788,"accession_number":"0001013762-25-002413","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.01","5.02","8.01","9.01"],"status":"ready","headline":"Rafael Holdings completes merger with Cyclo Therapeutics after shareholder approvals","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cyclo shareholders received 0.3525 shares of Rafael Class B common stock per share; Rafael issued approximately 7,132,228 shares.","Cyclo's Phase 3 TransportNPC trial for Niemann-Pick Type C1 is fully enrolled; 48-week interim analysis expected mid-2025.","Markus W. Sieger, former Cyclo Chairman, appointed to Rafael board as independent director.","Certain Cyclo warrants converted into Rafael warrants; new warrants to be publicly traded on NYSE American around March 31, 2025.","Cyclo common stock (CYTH) suspended from Nasdaq as of March 25, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176787,"accession_number":"0001013762-25-001736","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rafael Holdings stockholders approve share issuance for Cyclo Therapeutics merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share issuance proposal passed with 3,706,261 votes For (99.92%) vs. 1,571 Against.","Adjournment proposal also approved with 3,676,323 For (99.77%) and 32,783 Against.","Special meeting held March 20, 2025; both proposals were stockholder votes required to proceed with merger.","Transaction involves exchange of Rafael Class B common stock for Cyclo common stock under August 2024 merger agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176786,"accession_number":"0001213900-25-023789","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q2 net loss $4.6M vs prior year net income; merger with Cyclo pending","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M ($0.19/sh) for Q2 ended Jan 31, 2025 vs net income of $6.0M ($0.25/sh) a year ago.","Cash and equivalents at $48.3M as of January 31, 2025.","Merger with Cyclo Therapeutics (CYTH) expected to close in Q3 fiscal 2025 pending shareholder approvals.","Topline data from interim analysis (48 weeks) of Phase 3 Trappsol Cyclo for NPC1 expected mid-2025.","R&D expenses rose to $0.9M from $0.6M due to consolidation of Cornerstone and Day Three."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":205000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176785,"accession_number":"0001213900-25-011774","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Rafael Holdings and Cyclo Therapeutics extend merger deadline to March 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 2 to Merger Agreement extends the End Date from February 15, 2025 to March 31, 2025.","Rafael Holdings holds approximately 39.5% of Cyclo Therapeutics' outstanding common stock.","Extension allows additional time for SEC to declare the Form S-4 registration statement effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176784,"accession_number":"0001213900-25-003033","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rafael Holdings annual meeting elects all directors, approves 750K share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85.9%-89.2% of votes cast; broker non-votes 424,930.","Ratification of CohnReznick LLP as auditor approved with 99.93% votes (4,093,319 for).","Equity plan amendment to increase share pool by 750,000 shares approved with 85.25% votes (3,491,712 for).","Meeting held January 9, 2025; results reported in 8-K filed January 13, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193610,"accession_number":"0001213900-24-111976","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rafael Holdings converts $2.5M note into 39.5% stake in Cyclo Therapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Converted $2,500,000 of outstanding convertible note principal into 3,968,254 shares of Cyclo common stock.","Conversion price set at $0.63, the December 20, 2024 closing price of Cyclo's stock on Nasdaq.","Rafael now beneficially owns 39.5% of Cyclo Therapeutics' issued and outstanding common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193609,"accession_number":"0001213900-24-107632","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q1 FY2025 net loss $9.0M; Cyclo merger on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss attributable to Rafael Holdings of $9.0M ($0.37 per share) vs $3.6M loss a year ago.","Cash, cash equivalents and marketable securities of $54.3M as of October 31, 2024.","Pending merger with Cyclo Therapeutics (CYTH) expected to close in Q1 2025 after shareholder vote.","Cyclo Therapeutics' Phase 3 study for Trappsol Cyclo fully enrolled; interim results mid-2025.","R&D expenses $1.3M (up from $0.5M) on consolidation of Cornerstone and Day Three."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":128000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193608,"accession_number":"0001213900-24-095102","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings reports Q4 net loss $0.19/share; full year loss $1.45/share; merger with Cyclo ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss from continuing ops $4.5M ($0.19/diluted) vs gain $1.3M ($0.06) year ago.","Full year net loss $34.4M ($1.45/diluted) vs loss $8.4M ($0.36) prior year; includes $89.9M in-process R&D charge.","Cash and marketable securities $65.9M as of July 31, 2024.","Merger with Cyclo Therapeutics (CYTH) progressing; Phase 3 study fully enrolled, interim results mid-2025.","R&D expenses $4.2M for fiscal year, down from $6.3M due to winding down early-stage programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":128000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209911,"accession_number":"0001213900-24-071659","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Rafael Holdings to merge with Cyclo Therapeutics; deal values Cyclo at $0.95/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Rafael issues Class B common stock to Cyclo holders based on exchange ratio valuing Cyclo at $0.95/share and Rafael at net cash value.","Merger expected to close in Q4 2024, subject to shareholder approvals and SEC effectiveness of Form S-4.","Rafael will fund Cyclo's TransportNPC Phase 3 trial to 48-week interim analysis; enrollment complete, results expected mid-2025.","Cyclo directors enter 6-month lock-up; Howard Jonas agrees to vote in favor of share issuance.","Rafael also provides $3M convertible note to Cyclo under amended note purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209910,"accession_number":"0001213900-24-066336","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rafael Holdings: Director Mark McCamish resigns, replaced by Dr. Mark N. Stein","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark McCamish resigned as director of Rafael Holdings, effective August 5, 2024.","Dr. Mark N. Stein elected to the board and appointed to Audit, Compensation, and Corporate Governance committees.","Dr. Stein is a medical oncologist at Columbia University Irving Medical Center, specializing in genitourinary malignancies and immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228107,"accession_number":"0001213900-24-052893","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q3 net loss $32.4M ($1.36/sh) vs $1.4M loss YoY; driven by $89.9M IPR&D expense","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations of $32.4M ($1.36 diluted EPS) compared to $1.4M ($0.06) in prior-year quarter.","Q3 includes $89.9M in-process R&D expense from Cornerstone acquisition treatment, offset by $31.3M recovery of Cornerstone receivables.","Cash and marketable securities $72.4M as of April 30, 2024.","Increased Day Three Labs stake to 79% majority, began consolidating Jan 2024; Q3 R&D up to $1.5M from $0.7M.","Cyclo Therapeutics investment recorded $4.4M unrealized loss in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":472000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228106,"accession_number":"0001213900-24-046085","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K/A","filed_at":"2024-05-23T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Rafael Holdings files audited FY2023 financials of acquired Cornerstone; net income $4.2M but going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cornerstone FY2023 net income $4.2M (vs loss $10.2M FY2022) driven by $21.7M derivative gain; no product revenue.","Auditor expresses substantial doubt about going concern due to recurring losses and negative operating cash flows.","Total liabilities $88.9M vs assets $17.9M; accumulated deficit $261M; debt defaults on $12.2M convertible notes.","Acquisition of controlling interest closed March 13, 2024 after stockholder restructuring approvals.","Pro forma condensed combined financial statements filed as Exhibit 99.3; cash used in operations $7.2M in FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246869,"accession_number":"0001213900-24-022271","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q2 fiscal 2024 net income $5.9M; Day Three Labs stake raised to 79%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing ops $5.9M ($0.25 diluted EPS) vs loss of $3.3M (-$0.13) YoY.","Cash and marketable securities $71.7M at Jan 31, 2024.","Investment in Cyclo Therapeutics contributed $9.7M unrealized gain; Day Three Labs loss $1.6M.","Increased ownership in Day Three Labs to 79% majority interest; consolidating results.","Appointed Dr. John Goldberg as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":136000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246868,"accession_number":"0001213900-24-022185","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Rafael Holdings gains ~67% control of Cornerstone via debt conversion and $1.5M investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Converted $29.2M line of credit and $2.1M loan into 32.2M common shares at $0.97/sh.","Converted preferred stock into 6.1M common shares; invested $1.5M cash for 1.5M additional shares.","Now indirectly owns or controls 67.03% of Cornerstone's total outstanding equity.","RP Finance (37.5%-owned entity) received 3.66M shares for extending $21.9M debt maturity.","Majority of Cornerstone debt holders agreed to convert notes or extend maturity; mutual releases executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246867,"accession_number":"0001213900-24-003527","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rafael Holdings annual meeting: all directors elected, advisory votes pass, board sets triennial say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85-88% votes for: Bernstein 88.11%, Greenberg 86.56%, Jonas 86.42%, McCamish 86.56%, Weiss 85.19%.","Ratification of CohnReznick LLP as auditor approved with 99.70% votes for (4,109,091 for, 1,673 against, 10,786 abstentions).","Advisory vote on named executive officer compensation approved with 87.32% for (3,598,791 for, 12,916 against, 28,704 abstentions).","Advisory vote on frequency: 3,437,263 votes for three years; board determines future advisory votes every three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264314,"accession_number":"0001213900-23-095718","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q1 fiscal 2024 net loss narrows to $3.8M from $5.2M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations of $3.8M ($0.15/share) vs $5.2M ($0.22/share) a year ago.","Cash, cash equivalents and marketable securities of $72.1M as of Oct 31, 2023.","R&D expenses fell to $0.5M from $2.1M, driven by winding down early-stage programs.","G&A expenses decreased to $2.0M from $3.1M due to lower stock-based compensation and payroll.","CEO says company advancing portfolio and seeking strategic investments; continues supporting Cyclo Therapeutics (CYTH)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":68000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264313,"accession_number":"0001213900-23-081547","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings reports Q4 net income of $1.3M; full-year loss narrows to $8.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income from continuing ops $1.3M ($0.06/share) vs loss of $4.6M ($0.24/share) a year ago.","Full-year FY2023 net loss from continuing ops $8.7M ($0.36/share) vs $140.5M ($6.22/share) prior year which included large write-offs.","Cash, cash equivalents and marketable securities of $79.2M as of July 31, 2023.","Suspended Barer Institute activities; sold real estate for $33M net proceeds; invested in Cyclo Therapeutics (CYTH) and Day Three Labs.","R&D expenses reduced to $1.3M in Q4 from $1.8M; G&A down to $1.4M from $3.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264312,"accession_number":"0001013762-23-006974","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Rachel Jonas resigns from Rafael Holdings board effective Oct 25, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rachel Jonas resigned as director of Rafael Holdings, Inc. on October 25, 2023.","Resignation effective immediately; no replacement announced.","No reason for departure provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281549,"accession_number":"0001213900-23-065094","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Boris Pasche resigns from Rafael Holdings board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Boris Pasche resigned as director on August 7, 2023, due to a change in his principal employment.","Board accepted resignation effective August 8, 2023.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281548,"accession_number":"0001213900-23-062213","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.01"],"status":"ready","headline":"Howard Jonas gains control of Rafael Holdings via share transfer to his limited partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 31, 2023, eight trusts transferred 787,163 Class A shares (51.3% voting power) to a limited partnership controlled by Howard Jonas.","Howard Jonas, Executive Chairman, is sole manager of GP, giving him sole voting and dispositive power over the shares.","Following the transfer, Jonas becomes controlling stockholder; company becomes a controlled company under NYSE rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281547,"accession_number":"0001213900-23-062613","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K/A","filed_at":"2023-08-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rafael Holdings buys $5M of Cyclo Therapeutics shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 4,000,000 Cyclo common shares and a 7-year warrant for 4,000,000 more at $1.25 strike for $5M total.","The closing occurred on August 1, 2023 after Cyclo obtained stockholder approval on July 31, 2023.","This adds to an April 2023 purchase of 2,514,970 Cyclo shares and warrants at $0.71 strike.","The investment is part of a Securities Purchase Agreement first disclosed in the June 5, 2023 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300396,"accession_number":"0001213900-23-048570","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings reports Q3 net loss of $1.5M; invests $2.1M in Cyclo Therapeutics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing operations $1.5M ($0.06/sh) vs $5.0M ($0.25/sh) year ago.","Cash, equivalents and marketable securities $82.4M as of April 30, 2023.","Made initial $2.1M investment in Cyclo Therapeutics and agreement to invest additional $5M.","R&D expenses fell to $0.7M from $1.4M on winding down early-stage programs.","General and administrative expenses $2.3M for Q3, including $0.6M stock-based comp."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":211000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300395,"accession_number":"0001213900-23-045976","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rafael Holdings invests $5M in Cyclo Therapeutics for 4M shares and warrant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rafael Holdings to purchase 4M shares of Cyclo Therapeutics common stock plus warrant for additional 4M shares at $1.25 per share; total investment $5M.","Warrant exercisable at $1.25/share for 7 years from issuance.","Closing subject to Cyclo stockholder approval per Nasdaq Listing Rule 5635.","Rafael Holdings gets board designee (additional to CEO William Conkling) on Cyclo's board.","Registration rights agreement amended to require filing for resale of shares and warrant shares upon request."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300394,"accession_number":"0001213900-23-026722","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-04-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Rafael Holdings authorizes $5M share repurchase; expands strategic search beyond biopharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $5M of Class B common stock.","Company to seek investment opportunities within and beyond biopharma.","CEO cites balance sheet strength and confidence in long-term value creation.","Repurchases may be through open market or private transactions, subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320414,"accession_number":"0001213900-23-019930","cik":1713863,"company_name":"Rafael Holdings, Inc.","ticker":"RFL","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rafael Holdings Q2 FY2023 net loss $3.3M ($0.13/share); cash $88.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $3.3M for Q2 Jan 31 2023 vs $2.1M prior year; diluted EPS $0.13 loss.","Cash, cash equivalents and marketable securities $88.9M as of Jan 31, 2023.","R&D expenses $2.2M in Q2, down from $3.3M prior year due to winding down Barer Institute programs.","Six-month net loss $8.5M ($0.36/share) vs $130.9M ($5.86/share) prior year, which included $79.1M impairment and other charges.","G&A expenses $2.1M in Q2 vs credit of $1.7M prior year; includes $0.3M severance costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":140000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":71792334.30656932,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}